<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714957</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0672</org_study_id>
    <nct_id>NCT04714957</nct_id>
  </id_info>
  <brief_title>PITCHER (Peritoneal Carcinomatosis Heterogeneity)</brief_title>
  <official_title>PITCHER (Peritoneal Carcinomatosis Heterogeneity)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      How epigenetic deregulation affects gene expression patterns in subclones of the same tumor&#xD;
      is poorly known. Peritoneal Carcinomatosis (PC) is a condition in which multiple metastases&#xD;
      of the same abdominal tumor develop in the peritoneal cavity and intra-peritoneal organs,&#xD;
      thus defining different ecosystems of the same cancer. PITCHER addresses the variations in&#xD;
      epigenetically regulated gene expression between different subclones of PC in relation with&#xD;
      cell mechanoresponses, providing insights on how cancer epigenetic landscapes evolve under&#xD;
      environmental pressures and on strategies used by cancer cells to adapt to the transition&#xD;
      from one ecosystem to the other.&#xD;
&#xD;
      PITCHER is a network of 10 teams from Lyon, Grenoble and Marseille, based on data and&#xD;
      specimen collection of patients who have undergone a surgery for a peritoneal carcinomatosis&#xD;
      of ovarian or colorectal origin. PC lesions and eventually matched specimens of primary&#xD;
      tumors will be collected in the same patients at the time of the surgery or eventually&#xD;
      retrieved from already existing samples. Epigenetic landscapes will be analyzed by a&#xD;
      bioinformatics pipeline combining exome sequencing, transcriptome and methylome to identify&#xD;
      &quot;epigenetic hotspots&quot;, and their variations across lesions will be evaluated. These analyses&#xD;
      will be realized in fresh (when available) or pre-existing samples. When possible, organoid&#xD;
      cultures and animal models will be derived from multicellular structures in peritoneal fluids&#xD;
      and membrane, cytoskeletal and nucleoskeletal mechanoresponses will be characterized using&#xD;
      Atomic Force Microscopy. The role of tumor axonogenesis, a process of neo-formation of axon&#xD;
      fibers in tumors, will be addressed. Experimental studies of cell responses to therapy will&#xD;
      be performed to derive mathematical predictive models. All components will be integrated in a&#xD;
      systems biology map of PC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 2027</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>genetic and epigenetic data available for 20 &quot;multiplets&quot; biospecimens (peritoneal carcinomatosis + healthy tissue + primary tumor + tissue from other tumor metastasis - when applicable and available- )</measure>
    <time_frame>end of the inclusion period (September 2022)</time_frame>
    <description>The main endpoint is to implement a specific tissue collection of appropriate quality, assembling &quot;multiplets&quot; of biospecimens from the same patient, in order to construct a core database for research on mechanisms, biomarkers and actionable therapeutic targets in PC. This database will include molecular analysis by next-generation sequencing of whole-exome genetic, transcriptomic and epigenetic patterns of primary, peritoneal and metastatic lesions. &quot;Omics&quot; data are compiled using a data model also including anonymized information on histopathology and clinical history of treatments (when applicable)</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Secondary Peritoneal Cancers</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>construction of a database of genetic and epigenetic data on peritoneal carcinomatosis of colorectal or ovarian origin.</intervention_name>
    <description>Construction of a core database of genetic and epigenetic markers, in order to identify predictive biomarkers and potentially actionable targets for controlling the spread of peritoneal carcinomatosis.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tumor samples (peritoneal carcinomatosis, primary tumor, other tumor metastasis (when&#xD;
      applicable)), healthy tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cancer management and care for peritoneal carcinomatosis of digestive or&#xD;
        ovarian origin. PITCHER will include patients who will undergo surgery for peritoneal&#xD;
        carcinomatosis or patients who already undergone surgery for peritoneal carcinomatosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who accept to participate to the study&#xD;
&#xD;
          -  Men / women aged over 18 years&#xD;
&#xD;
          -  Patients with cancer management and care for peritoneal carcinomatosis of digestive or&#xD;
             ovarian origin&#xD;
&#xD;
          -  Patients had histologic/radiologic confirmation of peritoneal disease&#xD;
&#xD;
          -  Serology negative HIV, HEPATITIS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier GLEHEN, MD</last_name>
    <phone>+33 4 78 86 23 71</phone>
    <email>olivier.glehen@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara CALATTINI, CRA</last_name>
    <phone>+33 4 78 86 37 79</phone>
    <email>sara.calattini@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lyon SUD Hospital, Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier GLEHEN, MD</last_name>
      <phone>+33 4 78 86 23 71</phone>
      <email>olivier.glehen@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peritoneal carcinomatosis</keyword>
  <keyword>tumor heterogeneity</keyword>
  <keyword>epigenetic landscape</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

